Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
arcticnovartis
Mon, 05/05/2025 – 13:04
Read more about Novartis and Medicines for Malaria Venture announce…
Novartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
arcticnovartis
Tue, 04/29/2025 – 07:03
Read more about Novartis setzt die starke Dynamik fort mit zweis…
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
arcticnovartis
Tue, 04/29/2025 – 07:03
Read more about Novartis continues strong momentum with double-digit sales g…
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
arcticnovartis
Thu, 04/03/2025 – 02:19
Read more about…
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis
arcticnovartis
Mon, 03/31/2025 – 07:04
Read more about Novartis …
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
arcticnovartis
Fri, 03/28/2025 – 17:58
Read more about FDA approves Novartis radioligand thera…
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
arcticnovartis
Tue, 03/25/2025 – 07:18
Read more about Novartis to present new data at AAN, …
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
arcticnovartis
Tue, 03/25/2025 – 07:18
Read more about Novartis to present new data at AAN, …
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
arcticnovartis
Fri, 03/21/2025 – 00:19
Read more about Novartis receives third FDA approval for oral Fabhalta® (…
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
arcticnovartis
Fri, 03/21/2025 – 00:19
Read more about Novartis receives third FDA approval for oral Fabhalta® (…
